Zobrazeno 1 - 10
of 69
pro vyhledávání: '"D, Haraf"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M. McHugh, L.C. Das, Tanguy Y. Seiwert, K. Heath, Victoria M. Villaflor, Ralph R. Weichselbaum, D Haraf, Jonathan D. Cheng, E. E. Vokes, Ryan J. Brisson
Publikováno v:
European Journal of Cancer. 51:S105
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 6(3)
This study evaluated post-treatment performance and quality of life (QOL) outcome in head and neck cancer (HNC) patients treated with organ preservation, intensive chemoradiotherapy (FHX). Participants were 47 Stage II-IV HNC patients with no evidenc
Publikováno v:
Cancer. 77(11)
The goal of this investigation was to examine the relationship between, and application of, two disease specific quality of life (QL) measures currently being employed for head and neck cancer patients: the Functional Assessment of Cancer Therapy-Hea
Publikováno v:
Seminars in oncology. 22(3 Suppl 6)
Concomitant chemoradiotherapy holds promise in the therapy of advanced head and neck cancer. We have previously reported on the combination of 5-fluorouracil, hydroxyurea, and concomitant chemoradiotherapy administered on an alternate-week basis. In
Publikováno v:
Cancer treatment and research. 74
Publikováno v:
Cancer research. 53(16)
The molecular basis of tumor response to therapeutic radiation is poorly understood. Recent evidence suggests the p53 tumor suppressor gene may be involved in production of the G1 arrest seen following DNA damage by X-irradiation. It has further been
Autor:
Suzanne D. Conzen, Olwen Hahn, Gini F. Fleming, F. Olopade, V. Vanderpuye, Ruth Heimann, Nora Jaskowiak, D. Haraf
Publikováno v:
Journal of Clinical Oncology. 25:11097-11097
11097 Introduction: Therapy of unresectable LABC is challenging due to the need to resect local disease and prevent distant metastases. We conducted a phase I trial to determine the maximum tolerated dose of preoperative vinorelbine (VIN) combined wi
Publikováno v:
Neurophysiologie Clinique/Clinical Neurophysiology. 26:266-267